Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Announcements and Sponsorships by Biotechnology Companies and Major Drug Manufacturers - Research Report on Lilly, Geron,



   Announcements and Sponsorships by Biotechnology Companies and Major Drug
    Manufacturers - Research Report on Lilly, Geron, MannKind, Techne, and
                                  InterMune

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, December 2, 2013

NEW YORK, December 2, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Eli Lilly
& Co. (NYSE: LLY), Geron Corporation (NASDAQ: GERN), MannKind Corp. (NASDAQ:
MNKD), Techne Corp. (NASDAQ: TECH), and InterMune Inc. (NASDAQ: ITMN). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Eli Lilly & Co. Research Report

On November 19, 2013, Eli Lilly & Co. (Lilly) announced that Lilly Diabetes
will continue its national sponsorship of the American Diabetes Association's
(Association) Tour de Cure® annual cycling event for a second consecutive
year. According to the Company, in 2013, more than 65,000 cyclists in 89
events across 44 states raised more than $26 million to support the mission of
the Association. Additionally, the Company stated that Lilly employees, family
and friends joined together nationwide form 89 teams with 954 team riders, to
help raise $222,139 for people with diabetes, an increase of 211% over 2012.
Commenting on the release, Kevin Cammack, Senior Director of Marketing, U.S.,
Lilly Diabetes and Chair of Lilly Diabetes' 2014 Corporate Campaign, stated,
"Participating in this event was a moving experience for me, and I know how
important it is to our employees to connect with and support people with
diabetes in their own communities. We are proud to continue our support
knowing that through this collaboration and with a common goal, we are helping
the Association improve the lives of people with diabetes. We can't wait to
get out there and ride for people with diabetes once again." The Full Research
Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/977d_LLY

--

Geron Corporation Research Report

On November 26, 2013, Geron Corporation (Geron) announced that the Company's
President and CEO, John Scarlett, M.D., is scheduled to present an overview of
the Company at the 25th Annual Piper Jaffray Healthcare Conference. According
to the release, the presentation will take place on December 4, 2013, at 12:30
p.m. ET, in New York. Additionally, Geron stated that a live webcast of the
presentation will be made available to interested parties and will be archived
and available for replay for 30 days. The Full Research Report on Geron
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1ca9_GERN

--

MannKind Corp. Research Report

On November 27, 2013, MannKind Corp. (MannKind) announced that the Company
will present at The Piper Jaffray 25th Annual Healthcare Conference on
December 4, 2013. According to the release, the presentation will take place
at The New York Palace, New York, New York, at 10:00 a.m. ET. The Full
Research Report on MannKind Corp. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/044e_MNKD

--

Techne Corp. Research Report

On November 27, 2013, Techne Corp.'s (Techne) stock went down by 0.07% as it
closed the day at $85.93 per share. The Company's stock went down by 1.17%
over the past three trading days, compared to the Dow Jones Industrial Average
which went up by 0.20% during the same period. The Full Research Report on
Techne Corp. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b071_TECH

--

InterMune Inc. Research Report

On November 27, 2013, InterMune Inc.'s (InterMune) stock went up by 1.69%
closing the day at $13.81 per share. Over the previous three trading day
period the Company's stock went up by 6.56%, compared to the Nasdaq composite
which went up by 1.33% during the same trading period. The Full Research
Report on InterMune Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/dd8c_ITMN

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement